Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients

References

• Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993;11:5–14.
   PubMed Web of Science ®Google Scholar
• Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370–82.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Jansen G. Antimetabolites. In: Souhami RL, Tannock I, Hohenberger PHJC, editors. Oxford textbook of oncology. Oxford: Oxford University Press, 2001:663–713.
   Google Scholar
• Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729–35.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163–72.
   PubMed Web of Science ®Google Scholar
• Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247–57.
   PubMed Web of Science ®Google Scholar
• Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006;58:473–92.
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675–82.
   PubMed Web of Science ®Google Scholar
• Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465–70.
   PubMed Web of Science ®Google Scholar
• Fairbanks LD, Ruckemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999;342:143–52.
   PubMed Web of Science ®Google Scholar
• Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322–8.
   PubMed Web of Science ®Google Scholar
• Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005;54:273–80.
   PubMed Web of Science ®Google Scholar
• Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003;138:501–11.
   PubMed Web of Science ®Google Scholar
• Spurlock CF 3rd, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum 2012;64:1780–9.
   PubMed Web of Science ®Google Scholar
• Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James SJ, Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci USA 2003;100:6529–34.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001;167:2911–20.
   PubMed Web of Science ®Google Scholar
• Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619–32.
   PubMed Web of Science ®Google Scholar
• van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs – from bench to bedside. Nat Clin Pract Rheumatol 2007;3:26–34.
   PubMedGoogle Scholar
• Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012;15:183–210.
   PubMed Web of Science ®Google Scholar
• Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 2000;110:791–800.
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041–8.
   PubMed Web of Science ®Google Scholar
• Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189–98.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532–5.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Jansen G. Folate homeostasis and antiproliferative activity of folates and antifolates. Nutrition 2001;17:737–8.
   Google Scholar
• Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006;24:37–77.
   PubMed Web of Science ®Google Scholar
• Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991;51:5579–86.
   PubMed Web of Science ®Google Scholar
• Rhee MS, Galivan J, Wright JE, Rosowsky A. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 1994;45:783–91.
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Wright JE, Vaidya CM, Bader H, Forsch RA, Mota CE, Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl-L-ornithine (PT523). J Med Chem 1998;41: 5310–19.
   PubMedGoogle Scholar
• Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 1993;53:810–18.
   PubMed Web of Science ®Google Scholar
• Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997;3:911–21.
   PubMed Web of Science ®Google Scholar
• Boritzki TJ, Barlett CA, Zhang C, Howland EF. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 1996;14:295–303.
   Google Scholar
• Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003;42:1189–96.
   PubMed Web of Science ®Google Scholar
• Swierkot J, Miedzybrodzki R, Szymaniec S, Szechinski J. Activation dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2004;63:599–600.
   PubMed Web of Science ®Google Scholar
• Spurlock CF 3rd, Aune ZT, Tossberg JT, Collins PL, Aune JP, Huston JW 3rd, et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum 2011;63:2606–16.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205–19.
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol Pharmacol 1995;48:459–71.
   PubMed Web of Science ®Google Scholar
• Blits M, Jansen G, Vosslamber S, Assaraf YG, Verweij CL. Regulation of folate pathway related genes in methotrexate naïve and methotrexate treated patients with rheumatoid arthritis. Arthritis Rheum 2012;64:S911, meeting abstract 2154.
   Google Scholar
• Jansen G, Barr H, Kathmann I, Bunni MA, Priest DG, Noordhuis P, Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761–9.
   Web of Science ®Google Scholar
• Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004;43:267–71.
   PubMed Web of Science ®Google Scholar
• Arabelovic S, Sam G, Dallal GE, Jacques PF, Selhub J, Rosenberg IH, Preliminary evidence shows that folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis. J Am Coll Nutr 2007;26:453–5.
   PubMed Web of Science ®Google Scholar
• Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857–65.
   PubMed Web of Science ®Google Scholar
• Rots MG, Pieters R, Kaspers GJ, van Zantwijk CH, Noordhuis P, Mauritz R, Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 1999;93:1067–74.
   PubMedGoogle Scholar
• Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917–28.
   PubMed Web of Science ®Google Scholar
• Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009;11:e4.
   PubMed Web of Science ®Google Scholar
• Desmoulin SK, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 2010;78:577–87.
   Google Scholar
• van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, Lems WF, Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009;60:12–21.
   PubMed Web of Science ®Google Scholar
• van der Heijden JW, Oerlemans R, Tak PP, Assaraf YG, Kraan MC, Scheffer GL, Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis Rheum 2009;60:669–77.
   PubMed Web of Science ®Google Scholar
• Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1609–16.
   PubMed Web of Science ®Google Scholar
• Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240–7.
   PubMed Web of Science ®Google Scholar
• Castaneda O, Nair MG. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:862–4.
   PubMed Web of Science ®Google Scholar